When do we first feel pain?
Some have claimed that foetuses as young as twelve weeks can already be seen wincing in agony, while others have flat-out denied that even infants show any true signs of pain until long after birth.
New research from University College London offers fresh insights into this puzzle. By mapping the development of pain-processing networks in the brain – what researchers call the 'pain connectome' – scientists have begun to trace exactly when and how our capacity for pain emerges. What they discovered challenges simple answers about when pain 'begins'.
Get your news from actual experts, straight to your inbox. Sign up to our daily newsletter to receive all The Conversation UK's latest coverage of news and research, from politics and business to the arts and sciences.
The researchers used advanced brain imaging to compare the neural networks of foetuses and infants with those of adults, tracking how different components of pain processing mature over time. Until about 32 weeks after conception, all pain-related brain networks remain significantly underdeveloped compared with adult brains. But then development accelerates dramatically.
The sensory aspects of pain – the basic detection of harmful stimuli – mature first, becoming functional around 34 to 36 weeks of pregnancy. The emotional components that make pain distressing follow shortly after, developing between 36 and 38 weeks. However, the cognitive centres responsible for consciously interpreting and evaluating pain lag far behind, and remain largely immature by the time of birth, about 40 weeks after conception.
This staged development suggests that while late-term foetuses and newborns can detect and respond to harmful stimuli, they probably experience pain very differently from older children and adults. Most significantly, newborns probably can't consciously evaluate their pain – they can't form the thought: 'This hurts and it's bad!'
These findings represent the latest chapter in a long-running scientific debate that has swung dramatically over the centuries, often with profound consequences for medical practice.
For most physiologists in the 18th and 19th centuries, the perceived delicacy of the infant's body meant that it must be exquisitely sensitive to pain, so much so that some have had their doubts if infants ever felt anything else. Birth, in particular, was imagined to be an extremely painful event for a newborn.
However, advances in embryology during the 1870s reversed this thinking. As scientists discovered that infant brains and nervous systems were far less developed than adult versions, many began questioning whether babies could truly feel pain at all. If the neural machinery wasn't fully formed, how could genuine pain experiences exist?
This scepticism had troubling practical consequences. For nearly a century, many doctors performed surgery on infants without anaesthesia, convinced that their patients were essentially immune to suffering. The practice continued well into the 1980s in some medical centres.
Towards the end of the 20th century, public outrage about the medical treatment of infants and new scientific results turned the tables yet again. It was found that newborns exhibited many of the signs (neurological, physiological and behavioural) of pain after all, and that, if anything, pain in infants had probably been underestimated.
The reason why there has been endless disagreement about infant pain is that we cannot access their experiences directly.
Sure, we can observe their behaviour and study their brains, but these are not the same thing. Pain is an experience, something that's felt in the privacy of a person's own mind, and that's inaccessible to anyone but the person whose pain it is.
Of course, pain experiences are typically accompanied by telltale signs: be it the retraction of a body part from a sharp object or the increased activity of certain brain regions. Those we can measure. But the trouble is that no one behaviour or brain event is ever unambiguous.
The fact that an infant pulls back their hand from a pin prick may mean that it experiences the pricking as painful, but it may also just be an unconscious reflex. Similarly, the fact that the brain is simultaneously showing pain-related activity may be a sign of pain, but it may also be that the processing unfolds entirely unconsciously. We simply don't know.
Perhaps the infant knows. But even if they do, they can't tell us about their experiences yet, and until they can, scientists are left guessing. Fortunately, their guesses are becoming increasingly well informed, but for now, that is all they can be – guesses.
What would it take to get certainty? Well, it would require an explanation that connects our brains and behaviour to our conscious experiences. But so far, no scientifically respectable explanation of this kind has been forthcoming.
This article is republished from The Conversation under a Creative Commons license. Read the original article.
Laurenz Casser receives funding from the Leverhulme Trust.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Medscape
13 minutes ago
- Medscape
MRI Reveals Distinct ICI-Induced Joint Inflammation Patterns
TOPLINE: The whole-body MRI revealed similar inflammation levels in both patients with new arthralgia and those with new inflammatory arthritis after exposure to immune checkpoint inhibitors (ICIs), showing three distinct patterns of inflammation. METHODOLOGY: Researchers conducted a prospective imaging study from 2021 to 2024 including 60 patients (mean age, 65 years; 57% men; all White) from regional oncology services at a UK hospital who developed new musculoskeletal symptoms — arthralgia or inflammatory arthritis — after exposure to ICIs. Those with no history of rheumatologic autoimmune disease, active cancer, or recent joint pain served as healthy control individuals (n = 20; mean age, 62 years; 60% men). Participants underwent whole-body MRI to assess joint, tendon, bursal, entheseal, and spinal lesions, with imaging patterns analyzed over a 6-month follow-up. Imaging phenotypes were analyzed, applying a semiquantitative scoring system for synovitis, tenosynovitis, erosions, bursitis, and enthesitis, and compared between patients and healthy individuals. Scans were categorized into four groups on the basis of imaging patterns: polymyalgia rheumatica, peripheral inflammatory arthritis, spondyloarthropathy, and no specific pattern. TAKEAWAY: MRI showed no significant differences between patient groups but showed higher levels of inflammation and erosions in patients with arthralgia and those with inflammatory arthritis than in healthy control individuals, with median joint synovitis scores of 9.0 and 10.0 vs 2.0 and median joint erosion scores of 2.0 for both groups vs 0.0, respectively. After exposure to ICIs, the commonly affected joints were acromioclavicular (77%), glenohumeral (75%), wrist (73%), and metacarpophalangeal (59%) joints, with knee joint synovitis being more prevalent in patients with inflammatory arthritis than in those with arthralgia (67% vs 29%). Three distinct MRI patterns were identified: There was a polymyalgia rheumatica pattern in 12% of patients; peripheral inflammatory arthritis pattern in 37% of patients, with varying joint involvement (23% small joints, 32% large joints, and 45% both); and a pattern of overlap of both polymyalgia rheumatica and peripheral inflammatory arthritis in 20%. A total of 31% of patients did not meet any specific pattern criteria. Four of the five patients who required disease-modifying antirheumatic drugs to manage their symptoms were in the peripheral inflammatory arthritis group. IN PRACTICE: 'The finding of inflammation and erosions in patients with arthralgia without visible joint swelling suggests that clinical examination is insensitive and that the incidence of joint inflammation induced by immune checkpoint inhibitors is likely to be underestimated,' the experts wrote in a related comment. SOURCE: This study was led by Kate Harnden, MB ChB, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, University of Leeds, Leeds, England. It was published online on June 10, 2025, in The Lancet Rheumatology. LIMITATIONS: The imaging of feet and ankles was excluded from MRI scans owing to time constraints, which may have overlooked inflammation in those areas. The short follow-up period of 6 months limited the ability to capture long-term outcomes. Including patients with prior autoimmune diseases may have affected the results, and the predefined MRI patterns based on classical arthritis forms may have led to nonspecific pattern labeling. DISCLOSURES: This study was supported by the National Institute for Health and Care Research Leeds Biomedical Research Centre. One author reported receiving a bursary travel award, and another was supported by a fellowship program by AbbVie. One author disclosed receiving honoraria, and another received research grants and consulting fees from various sources including Gilead, Lilly, AbbVie, and Deepcare. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Yahoo
18 minutes ago
- Yahoo
Microplastics May Be Making E. Coli Infections Even More Dangerous, Scientists Say
A University of Illinois study found that certain charged nanoplastics can boost the virulence of foodborne pathogens like E. coli, making them harder to eliminate. The bacteria exposed to nanoplastics developed biofilms, which shield them from antibiotics and sanitation methods. A separate Boston University study found that microplastics enable bacteria to resist multiple antibiotics, raising concerns that regions with higher plastic pollution, such as low-income areas, may face increased risks of are truly everywhere. As the World Economic Forum explained, these tiny plastic particles measuring 5 millimeters or less have been found across land, oceans, the air, and throughout our food chain. They've also been detected in human blood and in the brain. We still don't know much about how they actually impact human health. However, a new study suggests that microplastics could have an unexpected effect: making foodborne illnesses even more dangerous than before. In April, researchers from the University of Illinois Urbana-Champaign published their study findings in the Journal of Nanobiotechnology, examining how nanoplastics, which are a mere 1 micrometer wide or smaller, react when they come into contact with foodborne pathogens, specifically E. coli O157:H7, a particularly harmful strain that can cause serious illness in humans. 'Other studies have evaluated the interaction of nanoplastics and bacteria, but so far, ours is the first to look at the impacts of microplastics and nanoplastics on human pathogenic bacteria," the study's senior author, Pratik Banerjee, who is also an associate professor in the department of food science and human nutrition and an Illinois Extension Specialist, shared in a statement. Related: How Microplastics Sneak Into Your Food — and What You Can Do About It Using three types of polystyrene-based nanoplastics — one with a positive charge, one with a negative charge, and one with no charge at all — the team discovered that these nanoparticles can significantly influence how bacteria grow, survive, and even how dangerous they become. In particular, those exposed to a positive charge. That's because the positive charge caused a "bacteriostatic" effect, which slowed but did not stop the E. coli from growing. Instead, it adapted, resumed growth, and formed biofilms, which make bacteria harder to kill. 'Just as a stressed dog is more likely to bite, the stressed bacteria became more virulent, pumping out more Shiga-like toxin, the chemical that causes illness in humans,' Banerjee said. The researcher noted that these biofilms form a "very robust bacterial structure and are hard to eradicate,' emphasizing that their goal was to observe what occurs "when this human pathogen, which is commonly transmitted via food, encounters these nanoplastics from the vantage point of a biofilm.' Although the research doesn't suggest that micro- and nanoplastics are the only cause of foodborne illness outbreaks, they point out that interactions like the ones they observed "lead to enhanced survival of pathogens with increased virulence traits."This isn't the only study highlighting the effects of microplastics on bacteria. In March, researchers from Boston University published their findings in the journal Applied and Environmental Microbiology, which showed that bacteria exposed to microplastics could become resistant to "multiple types of antibiotics commonly used to treat infections." Related: Are Plastic Bottles Leaking Microplastics Into Your Soda? Here's What Science Says They also specifically studied how E. coli (this time using MG1655, a non-pathogenic laboratory strain) reacted to microplastics, and, as Neila Gross, a PhD candidate in materials science and engineering and the lead author of the study, shared, 'The plastics provide a surface that the bacteria attach to and colonize." On those surfaces, Gross and her team also found that they created that dangerous biofilm, which "supercharged the bacterial biofilms," making it impossible for antibiotics to penetrate. 'We found that the biofilms on microplastics, compared to other surfaces like glass, are much stronger and thicker, like a house with a ton of insulation,' Gross added. 'It was staggering to see.' Furthermore, the BU team pointed out that while microplastics are everywhere, they are especially problematic in lower-income areas of the world that may lack the ability to control pollution flow. 'The fact that there are microplastics all around us, and even more so in impoverished places where sanitation may be limited, is a striking part of this observation,' Muhammad Zaman, a BU College of Engineering professor of biomedical engineering who studies antimicrobial resistance and refugee and migrant health, added. 'There is certainly a concern that this could present a higher risk in communities that are disadvantaged, and only underscores the need for more vigilance and a deeper insight into [microplastic and bacterial] interactions.' Read the original article on Food & Wine


Medscape
28 minutes ago
- Medscape
Robotic Bronchoscopy Proves Safe for Lung Lesion Sampling
TOPLINE: Robotic-assisted bronchoscopy showed safe navigation in significant number of most patients with peripheral pulmonary lesions needing a bronchoscopic diagnosis, with a diagnostic yield of 61.6% and minimal adverse events. METHODOLOGY: Researchers conducted a prospective observational study across 21 sites in the United States and Hong Kong to assess the safety, navigational success, and diagnostic yield of robotic-assisted bronchoscopy in patients with peripheral pulmonary lesions. They included 679 patients (median age, 69 years; 55.4% women) with lung lesions measuring 8-50 mm who underwent robotic- assisted bronchoscopy from December 2019 to September 2022. The primary composite endpoint was at least one incidence of device- or procedure-related adverse events such as pneumothorax requiring intervention, bleeding, or respiratory failure. Key secondary endpoints were confirmation of lesions by radial probe endobronchial ultrasound (R-EBUS) and diagnostic yield. TAKEAWAY: Device- or procedure-related adverse events occurred in 3.8% of patients, with pneumothorax requiring intervention being most common at 2.8%, followed by bleeding events of grade 2 at 0.9%. None of the patients experienced respiratory failure of grade 4 or higher. Robotic-assisted bronchoscopy provided access to lesions in 98.7% of cases, with lesions confirmed by R-EBUS in 91.7% of patients. The procedure demonstrated a malignancy detection sensitivity of 78.8%. The overall diagnostic yield of the procedure was 61.6% (95% CI, 57.9%-65.2%), which varied by lesion characteristics: 68.8% for lesions measuring > 20 mm, 56.2% for lesions measuring < 20 mm, and 66.7% when a bronchus sign was present. Predictors of a higher diagnostic yield were a history of chronic obstructive pulmonary disease/emphysema, the presence of a bronchus sign, a lesion size of > 20 mm, and a higher probability of malignancy. IN PRACTICE: 'This study is the largest RAB [robotic-assisted bronchoscopy] study to date and includes academic and community centers, providing generalizable estimates of safety and effectiveness in real-world clinical practice,' the authors wrote. SOURCE: This study was led by Septimiu Murgu, MD, University of Chicago, Department of Medicine, Section of Pulmonary and Critical Care Medicine, Chicago. It was published online on April 27, 2025, in CHEST. LIMITATIONS: This was a single-arm observational study. The investigators had varying levels of experience with robotic-assisted bronchoscopy, and decision-making processes were not uniform across sites. The small number of cone-beam computed tomography users limited meaningful interpretation of the diagnostic yield linked to this technology. DISCLOSURES: This study was supported by Auris Health, Inc, part of Johnson & Johnson MedTech. Few authors reported receiving research support from Auris Health and/or Johnson & Johnson MedTech while some reported being currently employed by subsidiaries of Johnson & Johnson. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.